Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Portfolio Growing

  • Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs
  • Active pharmaceutical ingredient market expected to exceed $239 billion by 2025
  • 19 patent applications filed in U.S. and internationally encompassing 44 countries
  • Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://cnw.fm/fGid9), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.

Lexaria recently received a broad-ranging U.S. patent award for DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and…

Read More >>

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply